Arcturus Therapeutics Holdings Inc
ARCT12.200USD
-0.100-0.81%
收盤 08/04, 16:00（美東）報價延遲15分鐘
330.88M總市值
虧損本益比TTM
關於 Arcturus Therapeutics Holdings Inc 公司
Arcturus Therapeutics Holdings Inc. 是一家全球信使 RNA 藥物和疫苗公司。該公司專注於傳染病疫苗的開發以及肝臟和呼吸系統罕見疾病領域的重大機遇。除了信使 RNA (mRNA) 平臺外，其脂質納米顆粒 (LNP) 遞送系統 LUNAR 還具有實現多種核酸藥物的潛力，其自擴增 mRNA 技術（自轉錄和複製 RNA (STARR) 技術）有可能在較低劑量水平下提供更持久的 RNA 和持續的蛋白質表達。該公司正在利用其 LUNAR 平臺和核酸技術開發和推進基於 mRNA 的疫苗和療法，用於治療具有重大未滿足醫療需求的傳染病和罕見遺傳疾病。其基於 STARR 技術平臺的 COVID-19 候選疫苗正在進行 II 期臨牀試驗。
公司簡介
公司代碼ARCT
公司名稱Arcturus Therapeutics Holdings Inc
上市日期May 22, 2013
CEOMr. Joseph E. Payne
員工數量174
證券類型Ordinary Share
年結日May 22
公司地址10628 Science Center Dr Ste 250
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編92121-1132
電話18589002660
網址https://arcturusrx.com/
公司代碼ARCT
上市日期May 22, 2013
CEOMr. Joseph E. Payne
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Andrew H. (Andy) Sassine
Mr. Andrew H. (Andy) Sassine
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
17.31%
BlackRock Institutional Trust Company, N.A.
7.82%
Nikko Asset Management Co., Ltd.
6.76%
The Vanguard Group, Inc.
6.67%
ARK Investment Management LLC
6.32%
Other
55.12%
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
17.31%
BlackRock Institutional Trust Company, N.A.
7.82%
Nikko Asset Management Co., Ltd.
6.76%
The Vanguard Group, Inc.
6.67%
ARK Investment Management LLC
6.32%
Other
55.12%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
43.62%
Investment Advisor
28.78%
Hedge Fund
13.66%
Individual Investor
7.88%
Research Firm
5.21%
Insurance Company
1.01%
Pension Fund
0.52%
Bank and Trust
0.30%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
391
27.00M
99.57%
-3.36M
2025Q1
403
27.75M
102.37%
-3.11M
2024Q4
400
27.43M
101.26%
-2.26M
2024Q3
404
26.95M
99.66%
-3.33M
2024Q2
409
27.79M
102.77%
-2.68M
2024Q1
391
28.99M
107.82%
+144.88K
2023Q4
376
27.09M
101.05%
-1.26M
2023Q3
373
26.77M
100.23%
-170.02K
2023Q2
355
26.49M
99.74%
-2.09M
2023Q1
361
26.10M
98.32%
-2.45M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Federated Hermes Global Investment Management Corp.
4.69M
17.31%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
7.82%
-29.89K
-1.39%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
1.93M
7.1%
-138.97K
-6.73%
Mar 31, 2025
The Vanguard Group, Inc.
1.74M
6.43%
+64.37K
+3.83%
Mar 31, 2025
ARK Investment Management LLC
2.01M
7.41%
+74.63K
+3.86%
Mar 31, 2025
Payne (Joseph E)
1.48M
5.46%
--
--
Apr 08, 2025
State Street Global Advisors (US)
1.28M
4.72%
-45.71K
-3.45%
Mar 31, 2025
Balyasny Asset Management LP
938.19K
3.46%
+389.43K
+70.97%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
825.77K
3.04%
-23.32K
-2.75%
Mar 31, 2025
Woodline Partners LP
780.44K
2.88%
-26.47K
-3.28%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ARK Genomic Revolution ETF
2.14%
WisdomTree BioRevolution Fund
1.67%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
iShares Genomics Immunology and Healthcare ETF
0.74%
AXS Green Alpha ETF
0.54%
Global X Genomics & Biotechnology ETF
0.41%
ALPS Medical Breakthroughs ETF
0.24%
SPDR S&P Biotech ETF
0.12%
iShares Micro-Cap ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
查看更多
ARK Genomic Revolution ETF
佔比2.14%
WisdomTree BioRevolution Fund
佔比1.67%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.93%
iShares Genomics Immunology and Healthcare ETF
佔比0.74%
AXS Green Alpha ETF
佔比0.54%
Global X Genomics & Biotechnology ETF
佔比0.41%
ALPS Medical Breakthroughs ETF
佔比0.24%
SPDR S&P Biotech ETF
佔比0.12%
iShares Micro-Cap ETF
佔比0.07%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.07%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
